Budesonide versus placebo in high-risk population with screen-detected lung nodules: Rationale, design and methodology

Contemporary Clinical Trials

Volumn 31, Issue 6, 2010, Pages 612-619

  Lazzeroni, Matteo ^a,b   Guerrieri Gonzaga, Aliana ^a   Serrano, Davide ^a   Varricchio, Maria Clara ^a   Veronesi, Giulia ^a   Radice, Davide ^a   Feroce, Irene ^a   Nardi Pantoli, Angela ^a   Lippman, Scott M ^c   Szabo, Eva ^d   Bonanni, Bernardo ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Budesonide; Chemoprevention; Low dose CT scan; Lung cancer; Screening

Indexed keywords

BUDESONIDE; PLACEBO;

ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EVENING DOSAGE; FEMALE; HIGH RISK POPULATION; HUMAN; HYDROCORTISONE RELEASE; LUNG NODULE; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MORNING DOSAGE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; SIDE EFFECT; STUDY DESIGN; TASTE DISORDER; VOICE CHANGE;

ADMINISTRATION, INHALATION; ALGORITHMS; BUDESONIDE; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MEDICATION ADHERENCE; MULTIPLE PULMONARY NODULES; RESEARCH DESIGN; SAMPLE SIZE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77957947159     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2010.08.006     Document Type: Article

References (23)

1. Pereira M.A., Li Y., Gunning W.T., Kramer P.M., Al Yaqoub F., Lubet R.A., et al. Prevention of mouse lung tumors by budesonide and its modulation of biomarkers. Carcinogenesis 2002, 23:1185-1192.
2. Wang Y., Zhang Z., Kastens E., Lubet R.A., You M. Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: differential chemopreventive effect of budesonide in wild-type and mutant A/J mice. Cancer Res 2003, 63:4389-4395.
3. Alyaqoub F.S., Tao L., Kramer P.M., Steele V.E., Lubet R.A., Gunning W.T., et al. Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budesonide and R115777 (Zarnestra MT). Carcinogenesis 2007, 28:124-129.
4. Parimon T., Chien J.W., Bryson C.L., McDonell M.B., Udris E.M., Au D.H. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:712-719.
5. Lam S., leRiche J.C., McWilliams A., MacAulay C., Dyachkova Y., Szabo E., et al. A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res 2004, 10:6502-6511.
6. Lee J.S., Lippman S.M., Benner S.E., Lee J.J., Ro J.Y., Lukeman J.M., et al. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol 1994, 12:937-945.
7. Henschke C.I., McCauley D.I., Yankelevitz D.F., Naidich D.P., McGuinness G., Miettinen O.S., et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999, 354:99-105.
8. Veronesi G., Bellomi M., Mulshine J.L., Pelosi G., Scanagatta P., Paganelli G., et al. Lung cancer screening with low-dose computed tomography: a non-invasive diagnostic protocol for baseline lung nodules. Lung Cancer 2008, 61:340-349.
9. Yamada S., Kohno T. Video-assisted thoracic surgery for pure ground-glass opacities 2cm or less in diameter. Ann Thorac Surg 2004, 77:1911-1915.
10. Kerr K.M. Pulmonary preinvasive neoplasia. J Clin Pathol 2001, 54:257-271.
11. Kim H.Y., Shim Y.M., Lee K.S., Han J., Yi C.A., Kim Y.K. Persistent pulmonary nodular ground-glass opacity at thin-section CT: histopathologic comparisons. Radiology 2007, 245:267-275.
12. Ohtsuka T., Watanabe K., Kaji M., Naruke T., Suemasu K. A clinicopathological study of resected pulmonary nodules with focal pure ground-glass opacity. Eur J Cardiothorac Surg 2006, 30:160-163.
13. Punturieri A., Szabo E., Croxton T.L., Shapiro S.D., Dubinett S.M. Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. J Natl Cancer Inst 2009, 101:554-559.
14. Crausman R.S., Lynch D.A., Mortenson R.L., King T.E., Irvin C.G., Hale V.A., et al. Quantitative CT predicts the severity of physiologic dysfunction in patients with lymphangioleiomyomatosis. Chest 1996, 109:131-137.
15. Paciocco G., Uslenghi E., Bianchi A., Mazzarella G., Roviaro G.C., Vecchi G., et al. Diffuse cystic lung diseases: correlation between radiologic and functional status. Chest 2004, 125:135-142.
16. Fahy J.V., Steiger D.J., Liu J., Basbaum C.B., Finkbeiner W.E., Boushey H.A. Markers of mucus secretion and DNA levels in induced sputum from asthmatic and from healthy subjects. Am Rev Respir Dis 1993, 147:1132-1137.
17. American Thoracic Society Standardization of Spirometry, 1994 Update. Am J Respir Crit Care Med 1995, 152:1107-1136.
18. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique-1995 update. Am J Respir Crit Care Med 1995, 152:2185-2198. American Thoracic Society.
19. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
20. Bellomi M., Veronesi G., Rampinelli C., Ferretti S., De F.E., Maisonneuve P. Evolution of lung nodules < or =5mm detected with low-dose CT in asymptomatic smokers. Br J Radiol 2007, 80:708-712.
21. van den Berg R.M., Teertstra H.J., van Z.N., van T.H., Visser C., Pasic A., et al. CT detected indeterminate pulmonary nodules in a chemoprevention trial of fluticasone. Lung Cancer 2008, 60:57-61.
22. Lee H.J., Goo J.M., Lee C.H., Park C.M., Kim K.G., Park E.A., et al. Predictive CT findings of malignancy in ground-glass nodules on thin-section chest CT: the effects on radiologist performance. Eur Radiol 2009, 19:552-560.
23. Pelosi G., Sonzogni A., Veronesi G., De C.E., Maisonneuve P., Spaggiari L., et al. Pathologic and molecular features of screening low-dose computed tomography (LDCT)-detected lung cancer: a baseline and 2-year repeat study. Lung Cancer 2008, 62:202-214.